The observations suggest that the consequences of NaV dysfunction are not only determined by their role in neuronal excitability but also depend on subtype-specific responses to inflammatory cues, shedding light on the relevance of inflammatory events in the onset and progression of epileptic syndromes related to NaV loss-of-function mutations.
Abstract
Epilepsy is one of the most common neurological disorders, affecting more than 50 million people worldwide. Among the genetic etiologies of epilepsy, variants in genes coding for ion channels are vastly represented and characterized. Notably, loss-of-function (LoF) mutations in voltage-gated sodium channels (NaV) genes can result in a wide range of phenotypes including West syndrome, autism spectrum disorder, or Dravet Syndrome. Although the implication of NaV subtypes in epileptic syndromes and the relationship between seizures and inflammation have been extensively described, subtype-specific neuronal responses to inflammation in the context of NaV loss-of-function remain poorly understood. In this study, we investigated the consequences of subtype-specific downregulation of NaV expression in primary mouse cortical neurons. Using shRNA-mediated silencing of Scn1a, Scn2a, or Scn8a, we generated neuronal cultures with reduced expression of NaV1.1, NaV1.2, or NaV1.6 and evaluated neuronal survival, inflammatory gene expression, and global transcriptomic responses under basal conditions and following an inflammatory challenge. Subtype-specific NaV downregulations did not produce a uniform phenotype. Rather, minor differences under basal conditions led to important discrepancies following exposure to an inflammatory stimulus. Notably, NaV1.1 reduction was associated with synaptic transcriptional changes, whereas NaV1.6 downregulation led to a substantial inflammatory signaling remodeling. Our observations suggest that the consequences of NaV dysfunction are not only determined by their role in neuronal excitability but also depend on subtype-specific responses to inflammatory cues. They notably shed light on the relevance of inflammatory events in the onset and progression of epileptic syndromes related to NaV loss-of-function mutations.
The first mouse model of SCN1A GoF epilepsy with heterozygous Cre-dependent expression of the recurrent patient variant Scn1a-p.R1636Q is developed, the first study of SCN1A GoF epilepsy in a preclinical model in vivo and further investigation in the Scn1aflox(R1636Q)mouse will yield new mechanistic insights into disea...
Sophie F. Hill, Z. Rosenthal, E. Goldberg· bioRxiv· 0 citations
It is shown that a pathogenic variant of the G protein subunit Gβ1 impairs activation of neuronal G-protein-coupled inwardly rectifying potassium (GIRK) channels by inhibitory synaptic GABAB receptors, which leads to increased dendritic excitability and longer duration dendritic calcium spikes in mouse hippocampal neur...
Sam Gritz, Anshul Voleti, Matthew S. Scarnati et al.· bioRxiv· 0 citations
The findings show that the two clinical directions of SCN8A disease have distinct tissue-level correlates and call for opposite therapeutic logic, channel or injury-cascade suppression for GoF and restoration of channel output for LoF, and identify a conserved, seizure-driven injury core as a tractable cross-disease ta...
Michael F. Hammer, Erfan Bahramnejad· bioRxiv· 0 citations
The divergence between morphological, electrophysiological and transcriptomic findings suggests that compensatory mechanisms may contribute to network hyperexcitability, and the graded severity of network alterations across STX1B variants correlates with the clinical phenotypes.
Carolin Haag, Felix Gsell, Oleg Vinogradov et al.· EBioMedicine· 0 citations
A systematic review of original studies investigated pharmacological modulation of KV3.1 using in vitro, in vivo, structural, and translational approaches highlights KV3.1 modulation as a context-dependent and increasingly precise pharmacological strategy for neurological and neurodevelopmental disorders.
Eider Núñez, Arantza Muguruza-Montero, Ane Arrizabalaga-Iriondo et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.